FDL169 is a novel F508del-CFTR corrector that increases the amount of F508del CFTR at the cell surface, has low risk of reduced activity upon chronic treatment and distributes well into lung tissue.

FDL169 Protects F508del CFTR from Chronic Inhibition by Ivacaftor

FDL169 has Enhanced Biodistribution to Lung

Summary and Conclusions

- FDL169 is a corrector with potency and efficacy equivalent to lumacaftor in vitro.
- In vitro, FDL169 increased the levels of mature F508del CFTR protein (Band C) to a similar extent as lumacaftor.
- Cells corrected with FDL169 are less sensitive to inhibition by prolonged exposure to ivacaftor.
- In human serum FDL169 is less protein bound than lumacaftor.
- FDL169 distributes better to the lungs than lumacaftor.
- FDL169 has favorable properties in vitro and in vivo that differentiate it from the lumacaftor.
- FDL169 is currently in Phase 1 clinical trials.